View Future GrowthDocMorris 過去の業績過去 基準チェック /06DocMorrisは12.1%の年平均成長率で業績を伸ばしているが、Consumer Retailing業界はgrowingで7.3%毎年増加している。売上は減少しており、年平均11%の割合である。主要情報12.12%収益成長率26.40%EPS成長率Consumer Retailing 業界の成長12.41%収益成長率-10.99%株主資本利益率-32.85%ネット・マージン-11.95%次回の業績アップデート19 Aug 2026最近の業績更新Reported Earnings • Mar 19Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Consumer Retailing industry in Europe.Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe.Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesPrice Target Changed • Apr 22Price target increased by 7.8% to CHF7.81Up from CHF7.24, the current price target is an average from 8 analysts. New target price is 12% above last closing price of CHF7.00. Stock is down 66% over the past year. The company is forecast to post a net loss per share of CHF1.59 next year compared to a net loss per share of CHF3.47 last year.お知らせ • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.Price Target Changed • Mar 23Price target decreased by 12% to CHF7.49Down from CHF8.48, the current price target is an average from 9 analysts. New target price is 86% above last closing price of CHF4.02. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF3.47 last year.Reported Earnings • Mar 19Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Consumer Retailing industry in Europe.New Risk • Feb 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF29m net loss in 3 years).分析記事 • Jan 24Not Many Are Piling Into DocMorris AG (VTX:DOCM) Just YetThere wouldn't be many who think DocMorris AG's ( VTX:DOCM ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...Price Target Changed • Dec 11Price target decreased by 23% to CHF9.38Down from CHF12.15, the current price target is an average from 9 analysts. New target price is 62% above last closing price of CHF5.80. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF2.32 next year compared to a net loss per share of CHF8.25 last year.分析記事 • Oct 23Is DocMorris (VTX:DOCM) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.Major Estimate Revision • Aug 26Consensus EPS estimates upgraded to CHF2.50 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CHF1.17b to CHF1.13b. 2025 losses expected to reduce from -CHF3.35 to -CHF2.50 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 26% next year. Consensus price target down from CHF14.28 to CHF12.98. Share price rose 4.9% to CHF7.11 over the past week.Price Target Changed • Aug 20Price target decreased by 7.5% to CHF13.39Down from CHF14.48, the current price target is an average from 10 analysts. New target price is 93% above last closing price of CHF6.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF2.33 next year compared to a net loss per share of CHF8.25 last year.Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe.分析記事 • Aug 06A Piece Of The Puzzle Missing From DocMorris AG's (VTX:DOCM) 28% Share Price ClimbSWX:DOCM 1 Year Share Price vs Fair Value Explore DocMorris's Fair Values from the Community and select yours DocMorris...Price Target Changed • Jul 16Price target decreased by 19% to CHF14.48Down from CHF17.89, the current price target is an average from 10 analysts. New target price is 88% above last closing price of CHF7.70. Stock is down 83% over the past year. The company is forecast to post a net loss per share of CHF3.06 next year compared to a net loss per share of CHF8.25 last year.Major Estimate Revision • Jul 03Consensus EPS estimates upgraded to CHF3.13 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF3.85 per share to -CHF3.13 per share. Revenue forecast reaffirmed at CHF1.17b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF17.89 to CHF16.80. Share price rose 7.7% to CHF6.72 over the past week.分析記事 • Jun 15Positive Sentiment Still Eludes DocMorris AG (VTX:DOCM) Following 33% Share Price SlumpTo the annoyance of some shareholders, DocMorris AG ( VTX:DOCM ) shares are down a considerable 33% in the last month...Price Target Changed • Jun 06Price target decreased by 9.5% to CHF18.01Down from CHF19.92, the current price target is an average from 12 analysts. New target price is 137% above last closing price of CHF7.61. Stock is down 88% over the past year. The company is forecast to post a net loss per share of CHF4.19 next year compared to a net loss per share of CHF8.25 last year.Major Estimate Revision • May 27Consensus EPS estimates upgraded to CHF4.92 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF5.59 to -CHF4.92 per share. Revenue forecast steady at CHF1.16b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF28.82 to CHF19.92. Share price fell 17% to CHF8.94 over the past week.Price Target Changed • May 26Price target decreased by 15% to CHF24.42Down from CHF28.82, the current price target is an average from 10 analysts. New target price is 158% above last closing price of CHF9.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of CHF5.15 next year compared to a net loss per share of CHF8.25 last year.お知らせ • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights OfferingNew Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).お知らせ • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issuePrice Target Changed • May 21Price target decreased by 12% to CHF26.82Down from CHF30.60, the current price target is an average from 10 analysts. New target price is 164% above last closing price of CHF10.17. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF5.59 next year compared to a net loss per share of CHF8.25 last year.Major Estimate Revision • May 15Consensus EPS estimates upgraded to CHF5.59 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF6.51 to -CHF5.59 per share. Revenue forecast unchanged from CHF1.16b at last update. Consumer Retailing industry in Switzerland expected to see average net income growth of 17% next year. Consensus price target down from CHF30.60 to CHF28.82. Share price fell 53% to CHF9.45 over the past week.Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • May 01DocMorris AG (VTX:DOCM) Stock Rockets 35% But Many Are Still Ignoring The CompanyDocMorris AG ( VTX:DOCM ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026Price Target Changed • Apr 17Price target decreased by 11% to CHF30.60Down from CHF34.30, the current price target is an average from 10 analysts. New target price is 51% above last closing price of CHF20.30. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF6.51 next year compared to a net loss per share of CHF8.25 last year.お知らせ • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.分析記事 • Apr 11Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.分析記事 • Mar 16The DocMorris AG (VTX:DOCM) Yearly Results Are Out And Analysts Have Published New ForecastsThere's been a notable change in appetite for DocMorris AG ( VTX:DOCM ) shares in the week since its annual report...分析記事 • Mar 14Sentiment Still Eluding DocMorris AG (VTX:DOCM)With a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Switzerland, you...Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.Price Target Changed • Jan 13Price target decreased by 14% to CHF40.50Down from CHF46.92, the current price target is an average from 12 analysts. New target price is 135% above last closing price of CHF17.21. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year.Price Target Changed • Jan 06Price target decreased by 9.6% to CHF43.92Down from CHF48.58, the current price target is an average from 12 analysts. New target price is 133% above last closing price of CHF18.84. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year.分析記事 • Dec 10It's Down 30% But DocMorris AG (VTX:DOCM) Could Be Riskier Than It LooksDocMorris AG ( VTX:DOCM ) shareholders that were waiting for something to happen have been dealt a blow with a 30...Price Target Changed • Dec 09Price target decreased by 7.5% to CHF48.58Down from CHF52.50, the current price target is an average from 12 analysts. New target price is 87% above last closing price of CHF25.96. Stock is down 64% over the past year. The company is forecast to post a net loss per share of CHF7.65 next year compared to a net loss per share of CHF10.07 last year.分析記事 • Oct 25DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An OpportunityWith a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Switzerland, you...Price Target Changed • Oct 07Price target decreased by 9.9% to CHF60.50Down from CHF67.17, the current price target is an average from 12 analysts. New target price is 93% above last closing price of CHF31.42. Stock is down 36% over the past year. The company is forecast to post a net loss per share of CHF7.62 next year compared to a net loss per share of CHF10.07 last year.分析記事 • Sep 22Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Price Target Changed • Sep 16Price target decreased by 9.1% to CHF70.92Down from CHF78.00, the current price target is an average from 12 analysts. New target price is 91% above last closing price of CHF37.20. Stock is down 32% over the past year. The company is forecast to post a net loss per share of CHF7.46 next year compared to a net loss per share of CHF10.07 last year.Breakeven Date Change • Sep 11No longer forecast to breakevenThe 12 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF6.48m in 2026. New consensus forecast suggests the company will make a loss of CHF16.1m in 2026.Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 22The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).Price Target Changed • Jul 17Price target decreased by 10% to CHF88.50Down from CHF98.58, the current price target is an average from 12 analysts. New target price is 88% above last closing price of CHF47.18. Stock is down 3.4% over the past year. The company is forecast to post a net loss per share of CHF7.23 next year compared to a net loss per share of CHF10.07 last year.お知らせ • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).Price Target Changed • Apr 18Price target increased by 7.5% to CHF99.24Up from CHF92.35, the current price target is an average from 12 analysts. New target price is 15% above last closing price of CHF86.20. Stock is up 127% over the past year. The company is forecast to post a net loss per share of CHF6.69 next year compared to a net loss per share of CHF10.07 last year.Price Target Changed • Apr 16Price target increased by 7.4% to CHF95.49Up from CHF88.91, the current price target is an average from 12 analysts. New target price is 8.6% above last closing price of CHF87.95. Stock is up 122% over the past year. The company is forecast to post a net loss per share of CHF6.56 next year compared to a net loss per share of CHF10.07 last year.Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF976.4m (down 39% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 22Price target increased by 7.2% to CHF85.27Up from CHF79.55, the current price target is an average from 11 analysts. New target price is approximately in line with last closing price of CHF84.90. Stock is up 133% over the past year.Price Target Changed • Mar 20Price target increased by 7.9% to CHF84.09Up from CHF77.92, the current price target is an average from 11 analysts. New target price is 5.6% above last closing price of CHF79.60. Stock is up 78% over the past year. The company is forecast to post a net loss per share of CHF5.64 next year compared to a net loss per share of CHF15.88 last year.Major Estimate Revision • Jan 19Consensus EPS estimates fall by 27%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.58 to -CHF5.81 per share. Revenue forecast unchanged at CHF967.8m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target of CHF77.92 unchanged from last update. Share price fell 3.4% to CHF72.90 over the past week.Major Estimate Revision • Jan 12Consensus EPS estimates upgraded to CHF4.58 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF6.15 to -CHF4.58 per share. Revenue forecast steady at CHF966.2m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target up from CHF69.00 to CHF77.92. Share price rose 5.5% to CHF74.20 over the past week.Price Target Changed • Jan 09Price target increased by 8.7% to CHF75.00Up from CHF69.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF78.50. Stock is up 145% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year.Price Target Changed • Jan 05Price target increased by 12% to CHF72.33Up from CHF64.58, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF70.30. Stock is up 135% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year.Price Target Changed • Dec 20Price target increased by 9.1% to CHF69.00Up from CHF63.27, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF67.00. Stock is up 150% over the past year. The company is forecast to post a net loss per share of CHF6.15 next year compared to a net loss per share of CHF15.88 last year.Major Estimate Revision • Nov 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.86 to -CHF5.38 per share. Revenue forecast unchanged at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price was steady at CHF53.30 over the past week.Major Estimate Revision • Nov 23Consensus EPS estimates upgraded to CHF3.46 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF4.86 to -CHF3.46 per share. Revenue forecast steady at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price rose 4.5% to CHF51.10 over the past week.New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change).お知らせ • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024Price Target Changed • Sep 19Price target increased by 10% to CHF64.86Up from CHF58.75, the current price target is an average from 11 analysts. New target price is 18% above last closing price of CHF54.75. Stock is up 62% over the past year. The company is forecast to post a net loss per share of CHF5.17 next year compared to a net loss per share of CHF15.88 last year.Major Estimate Revision • Aug 24Consensus EPS estimates upgraded to CHF3.21 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CHF1.08b to CHF979.6m. 2023 losses expected to reduce from -CHF8.75 to -CHF3.21 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 27% next year. Consensus price target up from CHF51.90 to CHF58.75. Share price rose 16% to CHF63.05 over the past week.Price Target Changed • Aug 21Price target increased by 10% to CHF57.33Up from CHF52.08, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF60.25. Stock is up 4.5% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF15.88 last year.Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.お知らせ • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Price Target Changed • Jan 24Price target decreased by 30% to CHF37.96Down from CHF53.96, the current price target is an average from 12 analysts. New target price is 11% above last closing price of CHF34.24. Stock is down 80% over the past year. The company is forecast to post a net loss per share of CHF14.63 next year compared to a net loss per share of CHF23.40 last year.Price Target Changed • Oct 14Price target decreased to CHF73.14Down from CHF78.73, the current price target is an average from 11 analysts. New target price is 179% above last closing price of CHF26.22. Stock is down 93% over the past year. The company is forecast to post a net loss per share of CHF15.14 next year compared to a net loss per share of CHF23.40 last year.Price Target Changed • Oct 04Price target decreased to CHF78.73Down from CHF85.27, the current price target is an average from 11 analysts. New target price is 150% above last closing price of CHF31.44. Stock is down 92% over the past year. The company is forecast to post a net loss per share of CHF15.55 next year compared to a net loss per share of CHF23.40 last year.お知らせ • Sep 22Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE).Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022. Reade Griffith completed the acquisition of an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022.分析記事 • Sep 07Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Price Target Changed • Aug 19Price target decreased to CHF107Down from CHF134, the current price target is an average from 10 analysts. New target price is 78% above last closing price of CHF59.85. Stock is down 82% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year.Reported Earnings • Aug 19First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 15%, compared to a 7.6% growth forecast for the Consumer Retailing industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Price Target Changed • Aug 09Price target decreased to CHF134Down from CHF146, the current price target is an average from 10 analysts. New target price is 123% above last closing price of CHF59.85. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year.お知らせ • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.Price Target Changed • Jul 14Price target decreased to CHF154Down from CHF166, the current price target is an average from 11 analysts. New target price is 128% above last closing price of CHF67.70. Stock is down 79% over the past year. The company is forecast to post a net loss per share of CHF16.39 next year compared to a net loss per share of CHF23.40 last year.お知らせ • Jun 01Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive BoardZur Rose Group AG announced that Betül Susamis Unaran Chief Strategy and Digital Officer as well as member of the Executive Board, has decided to pursue new career paths and leave the Zur Rose Group. In her almost three-year tenure, Ms. Unaran has been instrumental in the successful positioning of the Zur Rose Group and its transformation into the European healthcare ecosystem. In particular, she shaped and drove the rebranding of the DocMorris umbrella brand as well as the development of Health Journeys for people with obesity and diabetes. The implementation of the ecosystem strategy will be driven forward in all areas of the Zur Rose Group. The development of strategic partnerships will continue under the leadership of Anouk Robert, Group Director Partnerships and Branding.Price Target Changed • May 12Price target decreased to CHF197Down from CHF228, the current price target is an average from 10 analysts. New target price is 75% above last closing price of CHF113. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF15.50 next year compared to a net loss per share of CHF23.40 last year.お知らせ • Apr 06Zur Rose Group AG to Report First Half, 2022 Results on Aug 18, 2022Zur Rose Group AG announced that they will report first half, 2022 results on Aug 18, 2022Price Target Changed • Mar 21Price target decreased to CHF281Down from CHF313, the current price target is an average from 10 analysts. New target price is 98% above last closing price of CHF142. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CHF18.89 next year compared to a net loss per share of CHF14.95 last year.Price Target Changed • Mar 07Price target decreased to CHF303Down from CHF327, the current price target is an average from 10 analysts. New target price is 117% above last closing price of CHF139. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF18.65 next year compared to a net loss per share of CHF14.95 last year.Major Estimate Revision • Jan 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from CHF1.71b to CHF1.74b. Forecast EPS reduced from -CHF16.32 to -CHF18.18 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 12% next year. Consensus price target of CHF362 unchanged from last update. Share price fell 12% to CHF202 over the past week.Price Target Changed • Jan 07Price target decreased to CHF387Down from CHF417, the current price target is an average from 8 analysts. New target price is 79% above last closing price of CHF216. Stock is down 26% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year.Price Target Changed • Dec 31Price target decreased to CHF404Down from CHF437, the current price target is an average from 8 analysts. New target price is 72% above last closing price of CHF236. Stock is down 17% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year.収支内訳DocMorris の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史SWX:DOCM 収益、費用、利益 ( )CHF Millions日付収益収益G+A経費研究開発費31 Dec 251,124-134194030 Sep 251,093-128190030 Jun 251,062-121106031 Mar 251,052-114104031 Dec 241,017-97184030 Sep 241,010-97142030 Jun 241,003-97101031 Mar 24984-97109031 Dec 23969-118114030 Sep 23934-132118030 Jun 23899-146123031 Mar 23915-158121031 Dec 22931-171120030 Sep 221,156-202127030 Jun 221,381-232134031 Mar 221,554-229143031 Dec 211,727-226153030 Sep 211,673-193154030 Jun 211,619-160154031 Mar 211,548-148151031 Dec 201,477-136148030 Sep 201,431-112140030 Jun 201,385-88132031 Mar 201,370-70127031 Dec 191,356-52121030 Sep 191,314-45117030 Jun 191,272-39113031 Mar 191,240-39106031 Dec 181,207-39100030 Sep 181,166-3796030 Jun 181,125-3692031 Mar 181,061-3688031 Dec 17990-3683030 Sep 17953-34113030 Jun 17915-31144031 Mar 17900-21138031 Dec 16884-13135030 Sep 16873-4124030 Jun 168616114031 Mar 168474116031 Dec 158383116030 Sep 15857457030 Jun 158755650質の高い収益: DOCMは現在利益が出ていません。利益率の向上: DOCMは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DOCMは利益を出していないが、過去 5 年間で年間12.1%の割合で損失を削減してきた。成長の加速: DOCMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: DOCMは利益が出ていないため、過去 1 年間の収益成長をConsumer Retailing業界 ( 2.8% ) と比較することは困難です。株主資本利益率高いROE: DOCMは現在利益が出ていないため、自己資本利益率 ( -32.85% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-retailing 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 01:03終値2026/05/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DocMorris AG 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19 アナリスト機関Volker BosseBaader Helvea Equity ResearchSarah RobertsBarclaysGuillaume GallandBarclays16 その他のアナリストを表示
Reported Earnings • Mar 19Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Consumer Retailing industry in Europe.
Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe.
Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026
Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 22Price target increased by 7.8% to CHF7.81Up from CHF7.24, the current price target is an average from 8 analysts. New target price is 12% above last closing price of CHF7.00. Stock is down 66% over the past year. The company is forecast to post a net loss per share of CHF1.59 next year compared to a net loss per share of CHF3.47 last year.
お知らせ • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.
Price Target Changed • Mar 23Price target decreased by 12% to CHF7.49Down from CHF8.48, the current price target is an average from 9 analysts. New target price is 86% above last closing price of CHF4.02. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF3.47 last year.
Reported Earnings • Mar 19Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Consumer Retailing industry in Europe.
New Risk • Feb 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF29m net loss in 3 years).
分析記事 • Jan 24Not Many Are Piling Into DocMorris AG (VTX:DOCM) Just YetThere wouldn't be many who think DocMorris AG's ( VTX:DOCM ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...
Price Target Changed • Dec 11Price target decreased by 23% to CHF9.38Down from CHF12.15, the current price target is an average from 9 analysts. New target price is 62% above last closing price of CHF5.80. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF2.32 next year compared to a net loss per share of CHF8.25 last year.
分析記事 • Oct 23Is DocMorris (VTX:DOCM) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
Major Estimate Revision • Aug 26Consensus EPS estimates upgraded to CHF2.50 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CHF1.17b to CHF1.13b. 2025 losses expected to reduce from -CHF3.35 to -CHF2.50 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 26% next year. Consensus price target down from CHF14.28 to CHF12.98. Share price rose 4.9% to CHF7.11 over the past week.
Price Target Changed • Aug 20Price target decreased by 7.5% to CHF13.39Down from CHF14.48, the current price target is an average from 10 analysts. New target price is 93% above last closing price of CHF6.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF2.33 next year compared to a net loss per share of CHF8.25 last year.
Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe.
分析記事 • Aug 06A Piece Of The Puzzle Missing From DocMorris AG's (VTX:DOCM) 28% Share Price ClimbSWX:DOCM 1 Year Share Price vs Fair Value Explore DocMorris's Fair Values from the Community and select yours DocMorris...
Price Target Changed • Jul 16Price target decreased by 19% to CHF14.48Down from CHF17.89, the current price target is an average from 10 analysts. New target price is 88% above last closing price of CHF7.70. Stock is down 83% over the past year. The company is forecast to post a net loss per share of CHF3.06 next year compared to a net loss per share of CHF8.25 last year.
Major Estimate Revision • Jul 03Consensus EPS estimates upgraded to CHF3.13 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF3.85 per share to -CHF3.13 per share. Revenue forecast reaffirmed at CHF1.17b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF17.89 to CHF16.80. Share price rose 7.7% to CHF6.72 over the past week.
分析記事 • Jun 15Positive Sentiment Still Eludes DocMorris AG (VTX:DOCM) Following 33% Share Price SlumpTo the annoyance of some shareholders, DocMorris AG ( VTX:DOCM ) shares are down a considerable 33% in the last month...
Price Target Changed • Jun 06Price target decreased by 9.5% to CHF18.01Down from CHF19.92, the current price target is an average from 12 analysts. New target price is 137% above last closing price of CHF7.61. Stock is down 88% over the past year. The company is forecast to post a net loss per share of CHF4.19 next year compared to a net loss per share of CHF8.25 last year.
Major Estimate Revision • May 27Consensus EPS estimates upgraded to CHF4.92 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF5.59 to -CHF4.92 per share. Revenue forecast steady at CHF1.16b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF28.82 to CHF19.92. Share price fell 17% to CHF8.94 over the past week.
Price Target Changed • May 26Price target decreased by 15% to CHF24.42Down from CHF28.82, the current price target is an average from 10 analysts. New target price is 158% above last closing price of CHF9.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of CHF5.15 next year compared to a net loss per share of CHF8.25 last year.
お知らせ • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering
New Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).
お知らせ • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue
Price Target Changed • May 21Price target decreased by 12% to CHF26.82Down from CHF30.60, the current price target is an average from 10 analysts. New target price is 164% above last closing price of CHF10.17. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF5.59 next year compared to a net loss per share of CHF8.25 last year.
Major Estimate Revision • May 15Consensus EPS estimates upgraded to CHF5.59 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF6.51 to -CHF5.59 per share. Revenue forecast unchanged from CHF1.16b at last update. Consumer Retailing industry in Switzerland expected to see average net income growth of 17% next year. Consensus price target down from CHF30.60 to CHF28.82. Share price fell 53% to CHF9.45 over the past week.
Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • May 01DocMorris AG (VTX:DOCM) Stock Rockets 35% But Many Are Still Ignoring The CompanyDocMorris AG ( VTX:DOCM ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...
お知らせ • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026
Price Target Changed • Apr 17Price target decreased by 11% to CHF30.60Down from CHF34.30, the current price target is an average from 10 analysts. New target price is 51% above last closing price of CHF20.30. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF6.51 next year compared to a net loss per share of CHF8.25 last year.
お知らせ • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.
分析記事 • Apr 11Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
分析記事 • Mar 16The DocMorris AG (VTX:DOCM) Yearly Results Are Out And Analysts Have Published New ForecastsThere's been a notable change in appetite for DocMorris AG ( VTX:DOCM ) shares in the week since its annual report...
分析記事 • Mar 14Sentiment Still Eluding DocMorris AG (VTX:DOCM)With a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Switzerland, you...
Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.
Price Target Changed • Jan 13Price target decreased by 14% to CHF40.50Down from CHF46.92, the current price target is an average from 12 analysts. New target price is 135% above last closing price of CHF17.21. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year.
Price Target Changed • Jan 06Price target decreased by 9.6% to CHF43.92Down from CHF48.58, the current price target is an average from 12 analysts. New target price is 133% above last closing price of CHF18.84. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year.
分析記事 • Dec 10It's Down 30% But DocMorris AG (VTX:DOCM) Could Be Riskier Than It LooksDocMorris AG ( VTX:DOCM ) shareholders that were waiting for something to happen have been dealt a blow with a 30...
Price Target Changed • Dec 09Price target decreased by 7.5% to CHF48.58Down from CHF52.50, the current price target is an average from 12 analysts. New target price is 87% above last closing price of CHF25.96. Stock is down 64% over the past year. The company is forecast to post a net loss per share of CHF7.65 next year compared to a net loss per share of CHF10.07 last year.
分析記事 • Oct 25DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An OpportunityWith a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Switzerland, you...
Price Target Changed • Oct 07Price target decreased by 9.9% to CHF60.50Down from CHF67.17, the current price target is an average from 12 analysts. New target price is 93% above last closing price of CHF31.42. Stock is down 36% over the past year. The company is forecast to post a net loss per share of CHF7.62 next year compared to a net loss per share of CHF10.07 last year.
分析記事 • Sep 22Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Price Target Changed • Sep 16Price target decreased by 9.1% to CHF70.92Down from CHF78.00, the current price target is an average from 12 analysts. New target price is 91% above last closing price of CHF37.20. Stock is down 32% over the past year. The company is forecast to post a net loss per share of CHF7.46 next year compared to a net loss per share of CHF10.07 last year.
Breakeven Date Change • Sep 11No longer forecast to breakevenThe 12 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF6.48m in 2026. New consensus forecast suggests the company will make a loss of CHF16.1m in 2026.
Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 22The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
Price Target Changed • Jul 17Price target decreased by 10% to CHF88.50Down from CHF98.58, the current price target is an average from 12 analysts. New target price is 88% above last closing price of CHF47.18. Stock is down 3.4% over the past year. The company is forecast to post a net loss per share of CHF7.23 next year compared to a net loss per share of CHF10.07 last year.
お知らせ • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025
New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
Price Target Changed • Apr 18Price target increased by 7.5% to CHF99.24Up from CHF92.35, the current price target is an average from 12 analysts. New target price is 15% above last closing price of CHF86.20. Stock is up 127% over the past year. The company is forecast to post a net loss per share of CHF6.69 next year compared to a net loss per share of CHF10.07 last year.
Price Target Changed • Apr 16Price target increased by 7.4% to CHF95.49Up from CHF88.91, the current price target is an average from 12 analysts. New target price is 8.6% above last closing price of CHF87.95. Stock is up 122% over the past year. The company is forecast to post a net loss per share of CHF6.56 next year compared to a net loss per share of CHF10.07 last year.
Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF976.4m (down 39% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 22Price target increased by 7.2% to CHF85.27Up from CHF79.55, the current price target is an average from 11 analysts. New target price is approximately in line with last closing price of CHF84.90. Stock is up 133% over the past year.
Price Target Changed • Mar 20Price target increased by 7.9% to CHF84.09Up from CHF77.92, the current price target is an average from 11 analysts. New target price is 5.6% above last closing price of CHF79.60. Stock is up 78% over the past year. The company is forecast to post a net loss per share of CHF5.64 next year compared to a net loss per share of CHF15.88 last year.
Major Estimate Revision • Jan 19Consensus EPS estimates fall by 27%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.58 to -CHF5.81 per share. Revenue forecast unchanged at CHF967.8m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target of CHF77.92 unchanged from last update. Share price fell 3.4% to CHF72.90 over the past week.
Major Estimate Revision • Jan 12Consensus EPS estimates upgraded to CHF4.58 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF6.15 to -CHF4.58 per share. Revenue forecast steady at CHF966.2m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target up from CHF69.00 to CHF77.92. Share price rose 5.5% to CHF74.20 over the past week.
Price Target Changed • Jan 09Price target increased by 8.7% to CHF75.00Up from CHF69.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF78.50. Stock is up 145% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year.
Price Target Changed • Jan 05Price target increased by 12% to CHF72.33Up from CHF64.58, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF70.30. Stock is up 135% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year.
Price Target Changed • Dec 20Price target increased by 9.1% to CHF69.00Up from CHF63.27, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF67.00. Stock is up 150% over the past year. The company is forecast to post a net loss per share of CHF6.15 next year compared to a net loss per share of CHF15.88 last year.
Major Estimate Revision • Nov 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.86 to -CHF5.38 per share. Revenue forecast unchanged at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price was steady at CHF53.30 over the past week.
Major Estimate Revision • Nov 23Consensus EPS estimates upgraded to CHF3.46 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF4.86 to -CHF3.46 per share. Revenue forecast steady at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price rose 4.5% to CHF51.10 over the past week.
New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change).
お知らせ • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024
Price Target Changed • Sep 19Price target increased by 10% to CHF64.86Up from CHF58.75, the current price target is an average from 11 analysts. New target price is 18% above last closing price of CHF54.75. Stock is up 62% over the past year. The company is forecast to post a net loss per share of CHF5.17 next year compared to a net loss per share of CHF15.88 last year.
Major Estimate Revision • Aug 24Consensus EPS estimates upgraded to CHF3.21 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CHF1.08b to CHF979.6m. 2023 losses expected to reduce from -CHF8.75 to -CHF3.21 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 27% next year. Consensus price target up from CHF51.90 to CHF58.75. Share price rose 16% to CHF63.05 over the past week.
Price Target Changed • Aug 21Price target increased by 10% to CHF57.33Up from CHF52.08, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF60.25. Stock is up 4.5% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF15.88 last year.
Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.
お知らせ • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.
Price Target Changed • Jan 24Price target decreased by 30% to CHF37.96Down from CHF53.96, the current price target is an average from 12 analysts. New target price is 11% above last closing price of CHF34.24. Stock is down 80% over the past year. The company is forecast to post a net loss per share of CHF14.63 next year compared to a net loss per share of CHF23.40 last year.
Price Target Changed • Oct 14Price target decreased to CHF73.14Down from CHF78.73, the current price target is an average from 11 analysts. New target price is 179% above last closing price of CHF26.22. Stock is down 93% over the past year. The company is forecast to post a net loss per share of CHF15.14 next year compared to a net loss per share of CHF23.40 last year.
Price Target Changed • Oct 04Price target decreased to CHF78.73Down from CHF85.27, the current price target is an average from 11 analysts. New target price is 150% above last closing price of CHF31.44. Stock is down 92% over the past year. The company is forecast to post a net loss per share of CHF15.55 next year compared to a net loss per share of CHF23.40 last year.
お知らせ • Sep 22Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE).Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022. Reade Griffith completed the acquisition of an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022.
分析記事 • Sep 07Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Price Target Changed • Aug 19Price target decreased to CHF107Down from CHF134, the current price target is an average from 10 analysts. New target price is 78% above last closing price of CHF59.85. Stock is down 82% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year.
Reported Earnings • Aug 19First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 15%, compared to a 7.6% growth forecast for the Consumer Retailing industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Price Target Changed • Aug 09Price target decreased to CHF134Down from CHF146, the current price target is an average from 10 analysts. New target price is 123% above last closing price of CHF59.85. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year.
お知らせ • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.
Price Target Changed • Jul 14Price target decreased to CHF154Down from CHF166, the current price target is an average from 11 analysts. New target price is 128% above last closing price of CHF67.70. Stock is down 79% over the past year. The company is forecast to post a net loss per share of CHF16.39 next year compared to a net loss per share of CHF23.40 last year.
お知らせ • Jun 01Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive BoardZur Rose Group AG announced that Betül Susamis Unaran Chief Strategy and Digital Officer as well as member of the Executive Board, has decided to pursue new career paths and leave the Zur Rose Group. In her almost three-year tenure, Ms. Unaran has been instrumental in the successful positioning of the Zur Rose Group and its transformation into the European healthcare ecosystem. In particular, she shaped and drove the rebranding of the DocMorris umbrella brand as well as the development of Health Journeys for people with obesity and diabetes. The implementation of the ecosystem strategy will be driven forward in all areas of the Zur Rose Group. The development of strategic partnerships will continue under the leadership of Anouk Robert, Group Director Partnerships and Branding.
Price Target Changed • May 12Price target decreased to CHF197Down from CHF228, the current price target is an average from 10 analysts. New target price is 75% above last closing price of CHF113. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF15.50 next year compared to a net loss per share of CHF23.40 last year.
お知らせ • Apr 06Zur Rose Group AG to Report First Half, 2022 Results on Aug 18, 2022Zur Rose Group AG announced that they will report first half, 2022 results on Aug 18, 2022
Price Target Changed • Mar 21Price target decreased to CHF281Down from CHF313, the current price target is an average from 10 analysts. New target price is 98% above last closing price of CHF142. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CHF18.89 next year compared to a net loss per share of CHF14.95 last year.
Price Target Changed • Mar 07Price target decreased to CHF303Down from CHF327, the current price target is an average from 10 analysts. New target price is 117% above last closing price of CHF139. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF18.65 next year compared to a net loss per share of CHF14.95 last year.
Major Estimate Revision • Jan 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from CHF1.71b to CHF1.74b. Forecast EPS reduced from -CHF16.32 to -CHF18.18 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 12% next year. Consensus price target of CHF362 unchanged from last update. Share price fell 12% to CHF202 over the past week.
Price Target Changed • Jan 07Price target decreased to CHF387Down from CHF417, the current price target is an average from 8 analysts. New target price is 79% above last closing price of CHF216. Stock is down 26% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year.
Price Target Changed • Dec 31Price target decreased to CHF404Down from CHF437, the current price target is an average from 8 analysts. New target price is 72% above last closing price of CHF236. Stock is down 17% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year.